• Nachrichtendetail
• 

17.06.2024 14:02:15 - dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	JOHNSON + JOHNSON DL 1	853260	Frankfurt	144,360	19.08.24 17:54:19	-0,540	-0,37%	144,240	144,560	145,200	144,900